Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

Nicola A Hanania,1 Jorge F Maspero,2 David MG Halpin,3 David J Jackson,4,5 Reynold A Panettieri,6 Mario Castro,7 Christian Domingo,8 Nadia Daizadeh,9 Rebecca Gall,10 Juby A Jacob-Nara,11 Benjamin Ortiz,10 Michel Djandji,9 Paul J Rowe,11 Yamo Deniz10 1Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 2Fundación CIDEA, Buenos Aires, Argentina; 3University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK; 4School of Immunology and Microbial Sciences, King’s College London, London, UK; 5Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 6Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; 7University of Kansas School of Medicine, Kansas City, KS, USA; 8Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain; 9Sanofi, Cambridge, MA, USA; 10Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 11Sanofi, Bridgewater, NJ, USA Correspondence: Nicola A Hanania, Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA, Tel +1 713 798-2400, Email [email protected]